Benefit of carotid revascularisation for women with symptomatic carotid stenosis: protocol for a systematic review. by Bereznyakova, Olena et al.
UC Davis
UC Davis Previously Published Works
Title
Benefit of carotid revascularisation for women with symptomatic carotid stenosis: 
protocol for a systematic review.
Permalink
https://escholarship.org/uc/item/8wq95256
Journal
BMJ open, 9(11)
ISSN
2044-6055
Authors
Bereznyakova, Olena
Dewar, Brian
Dowlatshahi, Dar
et al.
Publication Date
2019-11-11
DOI
10.1136/bmjopen-2019-032140
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1Bereznyakova O, et al. BMJ Open 2019;9:e032140. doi:10.1136/bmjopen-2019-032140
Open access 
Benefit of carotid revascularisation for 
women with symptomatic carotid 
stenosis: protocol for a systematic review
Olena Bereznyakova,1 Brian Dewar,2 Dar Dowlatshahi,1 Virginia Howard,3 
Candyce Hamel  ,4 Sophia Gocan,1 Mark Fedyk,5 Michel Shamy4
To cite: Bereznyakova O, 
Dewar B, Dowlatshahi D, 
et al.  Benefit of carotid 
revascularisation for women 
with symptomatic carotid 
stenosis: protocol for a 
systematic review. BMJ Open 
2019;9:e032140. doi:10.1136/
bmjopen-2019-032140
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
032140).
Received 07 June 2019
Revised 29 August 2019
Accepted 11 October 2019
1Neurology, Ottawa Hospital, 
Ottawa, Ontario, Canada
2Neurology, Ottawa Hospital 
Research Institute, Ottawa, 
Ontario, Canada
3University of Alabama at 
Birmingham School of Public 
Health, Birmingham, Alabama, 
USA
4Ottawa Hospital Research 
Institute, Ottawa, Ontario, 
Canada
5Mount Allison University, 
Sackville, New Brunswick, 
Canada
Correspondence to
Dr Olena Bereznyakova;  
 nephab@ gmail. com
Protocol
© Author(s) (or their 
employer(s)) 2019. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
Strengths and limitations of this study
 ► This protocol was developed and prepared accord-
ing to the Preferred Reporting Items for Systematic 
Review and Meta- Analysis Protocols statement.
 ► This study benefits from a comprehensive search 
strategy, designed to retrieve a broad spectrum 
of relevant randomised controlled trials for the re-
search question.
 ► Heterogeneity will be explored using subgroup anal-
ysis based on a priori defined factors.
 ► Depending on our ability to extract sufficiently de-
tailed sex- based data, individual patient data anal-
ysis and network meta- analysis may be needed to 
analyse data in previously published trials.
AbStrACt
Introduction Carotid intervention in the form of 
endarterectomy or stenting is the current standard of care 
for the majority of patients with symptomatic high- grade 
carotid stenosis. However, some randomised controlled 
trials (RCT) have demonstrated that women benefited 
significantly less from intervention than men. It is unclear 
if this is a true phenomenon or a study sampling artefact, 
as women were severely under- represented in all RCTs of 
carotid revascularisation. A systematic review is needed to 
summarise the existing data and to answer the question of 
whether a women- only trial for symptomatic patients with 
ipsilateral carotid stenosis is scientifically necessary and 
ethically permissible.
Methods and analysis We will systematically search 
Medline, Embase, PubMed and the Cochrane libraries 
for all studies with data from RCTs that included women 
and compared either endarterectomy with stenting or 
revascularisation (by means of endarterectomy or stenting) 
with medical therapy in patients with symptomatic carotid 
stenosis. Search dates will be restricted to 1991–2018. 
Two reviewers will conduct screening search results, study 
selection, data extraction and quality assessment. We will 
include all studies reporting outcomes of interest. Planned 
subgroup analysis based on revascularisation technique, 
degree of stenosis and timing of intervention from the 
index event will be conducted with enough data.
Ethics and dissemination This research is exempt of 
ethics approval as no primary data will be collected. The 
results will be published in peer- reviewed journals and 
disseminated through national and international- level 
conferences and scientific meetings. The result of this 
comprehensive review will provide useful information on 
whether further RCTs are required to study a women- only 
population with symptomatic carotid disease.
PrOSPErO registration number CRD42019134967.
bACkgrOund
Carotid intervention (either endarterectomy 
or stenting) is the current standard of care 
for the majority of patients with symptomatic 
high- grade carotid stenosis.1 The benefits 
of surgical intervention appear to be highly 
time dependent, declining rapidly after the 
symptomatic event.2 However, the manage-
ment of carotid stenosis in women remains 
a topic of some controversy due to apparent 
differences in the likelihoods of benefit for 
men and women.3–5 It is not clear whether 
the observed difference between men and 
women is a true phenomenon or an artefact 
of study sampling, in that women were consis-
tently under- represented in early randomised 
controlled trials (RCT).6 7 If there is indeed a 
difference, it may reflect biological, psycho-
logical or sociological factors. For example, it 
is recognised that women take longer to get 
to hospital after onset of stroke, but they are 
also less likely to receive diagnostic tests and 
to receive secondary prevention drugs.8 9 As a 
consequence, women have worse outcomes, 
increased disability and decreased quality 
of life after ischaemic stroke.10 11 Women 
appear to experience their strokes earlier 
after the transient ischaemic attack (TIA) or 
minor stroke, potentially shortening the time 
window for effective intervention.11 12
In light of these potential differences, it is 
not clear whether stroke prevention strate-
gies for women and men should be different, 
particularly in the setting of symptomatic 
carotid stenosis. Some experts have called for 
repeating landmark trials, only with female 
patients.4 5 Is such a step necessary and ethical 
based on available knowledge?
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Rothwell et al2 were the first to report significant sex- 
related differences for surgical intervention of symptom-
atic carotid disease with combined analysis from the two 
earliest RCTs (European Carotid Surgery Trial (ECST) 
and North American Symptomatic Carotid Endarterec-
tomy Trial (NASCET)). This analysis showed that women 
in the medical group had a more rapid decline in the 
incidence of ipsilateral ischaemic stroke after TIA/minor 
stroke than did men. According to this analysis, the clear 
benefit of carotid endarterectomy (CEA) in women with 
70% stenosis was present only for the first 2 weeks after 
the last clinical event, whereas men could benefit up to 12 
weeks after the last event.2 Alternatively, there has been 
a suggestion that rates of poor outcomes are higher in 
women who undergo CEA. In Rothwell et al’s analysis, the 
30- day risk of perioperative stroke or death was higher 
in women compared with men (8.7% vs 6.8%; p=0.004).2 
Combination analysis from NASCET and the ASA and 
Carotid Endarterectomy studies showed an increased 
30- day mortality in women versus men (2.3% vs 0.8%; 
p=0.002). However, perioperative risk of stroke or death 
was not significantly different.13
The Carotid Revascularization Endarterectomy vs 
Stenting Trial (CREST)14 15 is the most recent and largest 
RCT comparing carotid artery stenting (CAS) to CEA 
for patients with symptomatic and asymptomatic carotid 
stenoses. Unlike earlier RCTs, CREST had a preplanned 
secondary subgroup analysis to address sex differences. 
Specifically, CREST was designed to achieve 90% power 
to detect an effect of sex on outcomes.14 According to 
this analysis, there were no increased periprocedural 
risks in symptomatic women in the CEA arm of CREST.16 
However, there was a higher periprocedural stroke risk in 
women for CAS than for CEA (5.5% vs 2.2%; p=0.013), 
while there were no significant differences in men (3.3% 
vs 2.4%; p=0.26).15 16
Other individual RCTs focusing on sex differences in 
outcomes of CAS versus CEA have provided limited and 
conflicting data for women with carotid stenosis.17–19 A 
combined sex- stratified analysis of patient data at 120 days 
after treatment from the three major European RCTs on 
carotid stenting in symptomatic patients performed by 
the Carotid Stenting Trialists’ Collaboration found that 
surgical risk was higher in women than in men, whereas 
risk of stenting was virtually unaffected by sex.20 However, 
their most recent long- term pooled analysis did not detect 
any significant treatment differences between sexes.21
Interpreting these results is challenging because 
women were severely under- represented in all major 
carotid revascularisation trials, with most trials enrolling 
less than 30% women.22 Although the most successful 
RCT representing women in carotid intervention was the 
CREST trial, its population only included 35% women.
Moreover, modern medical management of carotid 
disease has significantly advanced over the last 30 years. 
While high- potency statins, tight blood pressure control, 
antithrombotic agents, along with lifestyle modifications 
and smoking cessation are now standard of care, only 
15% of all patients in the NASCET trial were on any lipid- 
lowering agent.23
There are currently two ongoing trials comparing 
modern medical therapy to modern medical therapy and 
CAS/CEA in asymptomatic (CREST2)24 and lower risk 
symptomatic patients (ECST2).25 Overall, management 
of carotid stenosis in women is receiving an increased 
amount of attention. Several researchers have recently 
called for a sex- specific trial of carotid intervention in 
women with symptomatic stenosis.4 5 A modern, large 
RCT with a more pragmatic design, including an elderly 
population, may answer some questions related to the risk 
and benefits of carotid intervention in women. However, 
before proposing and conducting new research, a system-
atic review and meta- analysis should be done to identify 
whether the answer to the question is already available 
through existing data.26 To conduct a novel RCT when 
available data provide an answer to a clinical question 
would be unethical, in that it would deprive patients of 
standard therapies for multiple reasons: patients may be 
harmed, and resources would be wasted.
To date, few systematic reviews have investigated sex- 
related differences in the management of carotid stenosis. 
None has definitively answered the question of whether 
symptomatic women derive less benefit from carotid 
intervention. Some used combined data from asymp-
tomatic and symptomatic patients or did not include sex- 
related differences in their primary outcome.27 28 Others 
were weakened by the poor quality of analysed papers 
and included case series and very heterogeneous non- 
randomised studies.29
Therefore, we propose to perform a systematic review 
of all RCTs for symptomatic carotid stenosis comparing 
surgical intervention (CEA or CAS) and/or medical 
management that included women. Anticipating signif-
icant between- trial heterogeneity, network meta- analysis 
(NMA) and individual patient data analysis may be 
necessary.
rEvIEw quEStIOn
What are the benefits and harms of carotid intervention 
(endarterectomy and/or stenting) for women with symp-
tomatic carotid stenosis?
ObjECtIvES
The objective is to perform a systematic review of the 
evidence of carotid intervention in women with symptom-
atic carotid disease. The results from this review will help 
determine whether another trial is scientifically necessary 
and ethically permissible, and may help to inform the 
design of such a trial.
MEthOdS
This protocol was developed and prepared according 
to the Preferred Reporting Items for Systematic Review 
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Table 1 Inclusion and exclusion criteria
Inclusion Exclusion
Participants Participants with symptomatic (A) carotid stenosis (B)
A. Symptomatic is defined as ipsilateral TIA or minor stroke 
within 6 months.
B. Carotid stenosis is defined as greater than 50% stenosis (or 
the equivalent measurement).
Participants with asymptomatic carotid 
stenosis, carotid artery occlusions, carotid 
near- occlusion, concomitant coronary bypass 
surgery and redo surgeries for carotid stenosis
Interventions Management by endarterectomy and/or stenting Intervention done for tandem occlusions in 
the setting of acute ischaemic stroke, redo 
interventions, concomitant interventions 
with other surgery, comparisons of types or 
approaches for the same intervention
Comparators Medical therapy, endarterectomy and stenting
Outcomes Primary outcomes: composite of any stroke or death at 30 
days
Secondary outcomes:
1. 30- day disabling stroke or death, myocardial infarction, 
different types of stroke. Disabling stroke is defined as any 
stroke resulting in new or increased disability with a score 
on the modified Rankin Scale (mRS) of 3 or greater, 30 
days or more after stroke onset.
2. Intermediate and long- term outcome, including stroke 
recurrence, death and rates of restenosis according to 
individual studies’ prespecified outcomes
Timing Studies published from 1990 onwards.
Study design Randomised controlled trials (RCT), meta- analysis or 
systematic reviews reporting individual patient data from 
RCTs
Systematic reviews/meta- analysis, 
observational studies (eg, cohorts, case–
controls, cross sections), case series/reports 
and non- empirical studies (eg, editorials, 
comments, letters)
Language English and French
TIA, transient ischaemic attack.
and Meta- analysis Protocols (PRISMA- P) statement30 (see 
online supplementary appendix).
Eligibility criteria
The inclusion and exclusion criteria are presented in 
table 1.
data sources and search for studies
A search strategy will be developed through an itera-
tive process with the review team, including a medical 
library scientist. We will search Ovid Medline, Embase 
and PubMed. We will also search the Cochrane Library 
on Wiley. Search dates will be restricted to 1991–2018, 
based on the start of the modern era of carotid interven-
tion with the NASCET trial published in 1991.31 Strategies 
used a combination of controlled vocabulary (eg, ‘carotid 
stenosis’, ‘symptomatic stenosis’, ‘carotid revasculariza-
tion’, ‘carotid endarterectomy’, ‘carotid stenting’, ‘sex 
characteristics’, ‘carotid endarterectomy’, ‘stenting’) and 
keywords (eg, ‘women’, ‘female’, ‘sex’, ‘gender’, ‘symp-
tomatic’) (see online supplementary appendix).
Database searches will be supplemented by searching 
relevant websites, including  ClinicalTrials. gov. 
Bibliographies from relevant systematic reviews and 
meta- analysis will be searched to ensure relevant RCTs 
are captured.
Study selection
Duplicates across searches will be identified and removed 
using Covidence. Two authors will independently 
screen articles in a two- level process. Level 1 will involve 
screening based on title and abstract. Studies that score 
‘Yes’ or ‘Maybe’ after two reviews in this phase will be 
brought forward for full- text (level 2) evaluation. Full- 
text screening will use a procreated article screening 
form (see online supplementary appendix). We will use 
a ‘liberal accelerated’ method at this level, meaning that 
two reviews are required to exclude a study. The process 
of study selection will be described using a PRISMA flow 
diagram. A pilot exercise will occur at both levels, with 
100 records piloted at level 1 and 25 records piloted at 
level 2. This allows for testing of the screening questions 
and for calibration among reviewers. Articles not avail-
able electronically will be ordered through interlibrary 
loan. Those not received within 30 days of the request 
will be excluded with the reason for exclusion labelled 
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‘full text not available’. Where study eligibility is unclear 
during full- text screening, authors will be contacted twice, 
2 weeks apart, for additional information. If no response 
is received, the article will be excluded.
data collection process
Data will be independently extracted by two reviewers 
using a standardised data extraction form. We will pilot- 
test the data extraction form with five randomly selected 
articles to train data extractors as well as to assess the suffi-
ciency of the data extraction manual to ensure inter- rater 
reliability. We aim to achieve high agreement (≥80%) 
between two reviewers.
A data abstraction form will capture four types of data:
1. Bibliographic data. First author last name, publication 
year, country, funding source.
2. Study population data. Demographics (including 
age, sex), number of participants randomised to each 
group, relevant medical history, severity of ipsilateral 
carotid stenosis, type (TIA, retinal ischaemia, hemi-
spheric stroke) of most recent ipsilateral event, days 
elapsed between most recent event and treatment.
3. Outcome data. Combination of any stroke or death at 
30 days, disabling stroke or death, different types of 
stroke, myocardial infarction, local access complica-
tions, restenosis. Total number of randomised patients, 
the interventions being compared, and follow- up dura-
tion will be extracted from included studies.
4. Effect modifier data will be extracted on a per- trial ba-
sis (see the text that follows).
Data that may act as effect modifiers include:
1. Population characteristics (eg, mean or median age, 
proportion of female participants, functional status at 
presentation, medical history, smoking history, steno-
sis characteristics, including degree, location and pres-
ence of contralateral carotid stenosis).
2. Intervention characteristics (eg, CEA vs carotid stent-
ing/angioplasty vs medical management only, revas-
cularisation success rate, residual stenosis, restenosis 
rate).
After data extraction, two reviewers will resolve disa-
greements by discussion. A third reviewer will adjudicate 
in the event of unresolved disagreements.
risk of bias assessment
Risk of bias will be assessed by one reviewer, with verifica-
tion done by a second reviewer, using the Cochrane Risk 
of Bias Tool.32 We will determine an overall judgement 
per study and outcome class using the Cochrane guid-
ance. The studies’ level of quality will be presented in a 
table and narrative summary. The impact of study quality 
will be evaluated in the discussion. Where appropriate, 
a sensitivity analysis will be conducted excluding poor 
quality trials.
Strategy for data synthesis
We will assess patient characteristics, study design infor-
mation and event rates of the comparator arms. We will 
use various measures (I2) to assess for statistical hetero-
geneity. If quantitative synthesis is not appropriate or if 
the data are insufficient, the findings of our systematic 
review will be narratively reported. If quantitative anal-
ysis is possible, the results of individual outcomes will 
be pooled and meta- analysis will be performed using 
STATA. Furthermore, in case of a significant between- 
study heterogeneity, an NMA will be performed to estab-
lish multilevel comparisons among interventions. We will 
use the NMA PRISMA Extension to guide report prepara-
tion.33 Grading of Recommendations Assessment, Devel-
opment and Evaluation methods will be used for NMA to 
appraise the strength of evidence for all analyses.34
Analysis of subgroups or subsets
Planned subgroup analyses will be conducted where 
possible given available data. Specifically, we will examine 
the following comparisons:
1. Women with any intervention versus men with any 
intervention.
2. Women with any intervention versus women without 
intervention.
3. The above, stratified by degree of stenosis, with 50%–
69% and 70%–99% being commonly reported thresh-
olds.
4. The above, based on the intervention technique (end-
arterectomy or stenting).
5. The above, based on timing of intervention after the 
index event (within 48 hours, within 2 weeks, within 4 
weeks, within 12 weeks and greater than 12 weeks).
PAtIEnt And PublIC InvOlvEMEnt
No patients will be involved.
COnCluSIOn
We aim to compare treatment outcomes between sexes 
in patients with symptomatic carotid artery stenosis. The 
results of this work may help clinicians to guide manage-
ment of symptomatic carotid stenosis in women and may 
also act as a useful tool in patient selection for interven-
tion in this group population. We also hope that this work 
will provide useful information on whether an RCT for 
women with symptomatic carotid stenosis is scientifically 
necessary and ethically permissible.
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